{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:47:08Z","timestamp":1775076428722,"version":"3.50.1"},"reference-count":116,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007771","name":"Medical University of Silesia","doi-asserted-by":"publisher","award":["PCN-1-055\/N\/1\/1"],"award-info":[{"award-number":["PCN-1-055\/N\/1\/1"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hypercholesterolemia plays a crucial role in the development of atherosclerosis, but it remains an undertreated and underdiagnosed disease. Taking into consideration the high prevalence of lipid disorders, long duration of the asymptomatic course of the disease, life-threatening complications resulting from inaccurate therapy, and stringent treatment goals concerning LDL cholesterol level in the prevention of cardiovascular events, novel lipid-lowering therapies have been introduced in the last few years. In this article, a drug belonging to the group of small interfering RNA (siRNA) called inclisiran is described. It is a novel molecule that increases the number of LDL receptors (LDLRs) on the surface of hepatic cells by preventing the formation of proprotein convertase subtilisin\/kexin type 9 (PCSK9) responsible for the degradation of LDLRs. With great potential for lowering plasma LDL cholesterol level, high liver specificity, comfortable dosing regimen, and good tolerance without significant adverse effects, it could play an important part in future hypolipemic therapies.<\/jats:p>","DOI":"10.3390\/ijms24076858","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T08:41:52Z","timestamp":1680770512000},"page":"6858","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Inclisiran\u2014A Revolutionary Addition to a Cholesterol-Lowering Therapy"],"prefix":"10.3390","volume":"24","author":[{"given":"Adrianna","family":"Dec","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Niemiec","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliza","family":"Wojciechowska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-8785","authenticated-orcid":false,"given":"Mateusz","family":"Malig\u0142\u00f3wka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Bu\u0142dak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Bo\u0142dys","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7228-2906","authenticated-orcid":false,"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia in Katowice, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/1568026616666160824102322","article-title":"Coumarin and Derivates as Lipid Lowering Agents","volume":"17","author":"Tejada","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.5603\/EP.a2019.0041","article-title":"Endocrine diseases as causes of secondary hyperlipidemia","volume":"70","author":"Marek","year":"2019","journal-title":"Endokrynol. Pol."},{"key":"ref_3","first-page":"29","article-title":"Secondary hypertriglyceridemia","volume":"33","author":"Yago","year":"2021","journal-title":"Clin. Investig. Arterioscler."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.001","article-title":"Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collabo-ration","volume":"22","author":"Akram","year":"2016","journal-title":"Atheroscler. Suppl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11883-014-0482-5","article-title":"Familial hypercholesterolemia--epidemiology, diagnosis, and screening","volume":"17","author":"Singh","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_6","unstructured":"Huhtaniemi, I., and Martini, L. (2019). Encyclopedia of Endocrine Diseases, Academic Press. [2nd ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Benito-Vicente, A., Uribe, K.B., Jebari, S., Galicia-Garcia, U., Ostolaza, H., and Martin, C. (2018). Molecular Sciences Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. Int. J. Mol. Sci, 19.","DOI":"10.3390\/ijms19113426"},{"key":"ref_8","first-page":"S139","article-title":"Epidemiology and management of hyperlipidemia","volume":"23","author":"Karr","year":"2017","journal-title":"Am. J. Manag. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e32728","DOI":"10.1097\/MD.0000000000032728","article-title":"Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews","volume":"102","author":"Li","year":"2023","journal-title":"Medicine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/jcph.2045","article-title":"Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction","volume":"62","author":"Smith","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_11","first-page":"569","article-title":"Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts\u2019 opinion. The compromise between EBM and possibilities in healthcare","volume":"18","author":"Banach","year":"2022","journal-title":"Arch. Med. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","article-title":"Hyperlipidemia as a Risk Factor for Cardiovascular Disease","volume":"40","author":"Nelson","year":"2012","journal-title":"Prim. Care Clin. Off. Pract."},{"key":"ref_13","unstructured":"SCORE2 Working Group and ESC Cardiovascular Risk Collaboration (2021). SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J., 42, 2439\u20132454."},{"key":"ref_14","unstructured":"Ritchie, H., Spooner, F., and Roser, M. (2023, January 20). \u201cCauses of Death\u201d. Published Online at OurWorldInData.org. Available online: https:\/\/ourworldindata.org\/causes-of-death."},{"key":"ref_15","unstructured":"(2022, October 25). The Top 10 Causes of Death\u2013Factsheet. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC Scientific Document Group, 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modifi-cation to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardi-ology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/hrt.2007.134890","article-title":"Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: A validation study","volume":"94","author":"Coupland","year":"2008","journal-title":"Heart"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.286.2.180","article-title":"Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation","volume":"286","author":"Grundy","year":"2001","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of Coronary Heart Disease Using Risk Factor Categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosis.2004.12.026","article-title":"A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study","volume":"181","author":"Cooper","year":"2005","journal-title":"Atherosclerosis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1194\/jlr.P085522","article-title":"Effects of oils and solid fats on blood lipids: A systematic review and network meta-analysis","volume":"59","author":"Schwingshackl","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","unstructured":"Feingold, K.R., Anawalt, B., and Blackman, M.R. (2023, January 20). Lifestyle Changes: Effect of Diet, Exercise, Functional Food, and Obesity Treatment on Lipids and Lipoproteins, Endotext [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326737\/."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.plefa.2011.02.001","article-title":"A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: Results of a meta-analysis of randomized, placebo-controlled trials","volume":"85","author":"Poon","year":"2011","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1177\/2047487317716500","article-title":"Food supplements with red yeast rice: More regulations are needed","volume":"24","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Nguyen, T., Karl, M., and Santini, A. (2017). Red Yeast Rice. Foods, 6.","DOI":"10.3390\/foods6030019"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., and Wright, M. (2018). Scientific opinion on the safety of monacolins in red yeast rice. EFSA J., 16, e05368.","DOI":"10.2903\/j.efsa.2018.5368"},{"key":"ref_28","unstructured":"The American College of Cardiology (2015, December 09). Odyssey High FH. Presented at Henry N. Ginsberg at the American Heart Association Scientific Sessions, Chicago, IL, USA. Available online: http:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2014\/11\/18\/15\/23\/odyssey-high-fh."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_30","first-page":"55","article-title":"Treatment of hypercholesterolaemia in cardiovascular diseases\u2014What target, which statin, what dose?","volume":"9","year":"2014","journal-title":"Folia Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu. Rev. Pharmacol Toxicol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4103\/2230-8210.163106","article-title":"Pleiotropic effects of statins","volume":"19","author":"Kavalipati","year":"2015","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"687585","DOI":"10.3389\/fcvm.2021.687585","article-title":"Hydrophilic or Lipophilic Statins?","volume":"8","author":"Climent","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.medcli.2017.11.030","article-title":"Statins: Pros and cons","volume":"150","author":"Mammen","year":"2018","journal-title":"Med. Clin."},{"key":"ref_36","first-page":"631","article-title":"Statin Therapy: Review of Safety and Potential Side Effects","volume":"32","author":"Ramkumar","year":"2016","journal-title":"Acta Cardiol. Sin."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00003495-200363070-00007","article-title":"Lovastatin extended release: A review of its use in the management of hypercholesterolaemia","volume":"63","author":"Curran","year":"2003","journal-title":"Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1517\/14656566.5.12.2583","article-title":"Simvastatin: A review","volume":"5","author":"Pedersen","year":"2004","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_39","first-page":"CD010254","article-title":"Lipid lowering efficacy of rosuvastatin","volume":"2014","author":"Adams","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/2047487315598710","article-title":"Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis","volume":"23","author":"Karlson","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/VHRM.S33664","article-title":"Ezetimibe therapy: Mechanism of action and clinical update","volume":"8","author":"Toth","year":"2012","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1742-1241.2007.01592.x","article-title":"Ezetimibe-associated adverse effects: What the clinician needs to know","volume":"62","author":"Florentin","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2722 people: Systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J. Intern. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2040622316672544","article-title":"Ezetimibe: An update on its clinical usefulness in specific patient groups","volume":"8","author":"Hammersley","year":"2016","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"RACING investigators. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5603\/FC.2015.0081","article-title":"Gdy statyna to za ma\u0142o\u2014Skojarzenie statyny z ezetimibem w terapii hipercholesterolemii","volume":"10","author":"Starzyk","year":"2016","journal-title":"Folia Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia","volume":"105","author":"Gaudet","year":"2002","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1368-5031.2004.00289.x","article-title":"Efficacy and safety of ezetimibe coadministered with statins: Randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia","volume":"58","author":"Davidson","year":"2004","journal-title":"Int. J. Clin. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0002-9149(02)03236-8","article-title":"Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia","volume":"91","author":"Kerzner","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"764038","DOI":"10.3389\/fcvm.2021.764038","article-title":"Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications","volume":"8","author":"Xia","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"598649","DOI":"10.3389\/fphys.2020.598649","article-title":"Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin\/Kexin Type 9","volume":"11","author":"Wolf","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1073\/pnas.051630598","article-title":"An orches-trated gene expression component of neuronal programmed cell death revealed by cDNA array analysis","volume":"98","author":"Chiang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pathol.2018.10.012","article-title":"PCSK9: From biology to clinical applications","volume":"51","author":"Blanchard","year":"2018","journal-title":"Pathology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.abb.2017.06.001","article-title":"Hypercholesterolemia: The role of PCSK9","volume":"625\u2013626","author":"Melendez","year":"2017","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100003","DOI":"10.1194\/jlr.RA120000964","article-title":"Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9","volume":"62","author":"Oleaga","year":"2021","journal-title":"J. Lipid Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase (PC) PCSK9 is inactivated by furin and\/or PC5\/6A: Functional consequences of natural mutations and post-translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jjcc.2020.04.006","article-title":"Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction","volume":"76","author":"Nakamura","year":"2020","journal-title":"J. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jacl.2017.01.005","article-title":"Mature proprotein convertase subtilisin\/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia","volume":"11","author":"Kataoka","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"43482","DOI":"10.1074\/jbc.M112.380618","article-title":"Furin-cleaved proprotein convertase subtilisin\/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels","volume":"287","author":"Lipari","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jacl.2022.06.009","article-title":"Small interfering ribonucleic acid for cholesterol lowering\u2013Inclisiran: Inclisiran for cholesterol lowering","volume":"16","author":"Soffer","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","article-title":"Inclisiran-New hope in the management of lipid disorders?","volume":"14","author":"Penson","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","article-title":"Inhibiting PCSK9\u2014Biology beyond LDL control","volume":"15","author":"Stoekenbroek","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: A new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Dis-ease","volume":"146","author":"Giugliano","year":"2022","journal-title":"Circulation"},{"key":"ref_68","unstructured":"(2015, December 09). Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia. Available online: http:\/\/www.prnewswire.com\/news-releases\/regeneron-and-sanofi-announce-positive-topline-results-from-first-phase-3-trials-evaluating-monthly-dosing-of-alirocumab-in-patients-with-hypercholesterolemia-300017492.html."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2014","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"174178","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: Mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14740338.2022.1988568","article-title":"Inclisiran: A small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia","volume":"21","author":"Banerjee","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ranasinghe, P., Addison, M.L., Dear, J.W., and Webb, D.J. Small interfering RNA: Discovery, pharmacology and clinical de-velopment-An introductory review. Br. J. Pharmacol., 2022.","DOI":"10.1111\/bph.15972"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"114432","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: Updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_75","first-page":"133","article-title":"RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies","volume":"384","author":"Traber","year":"2022","journal-title":"Experiment"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: First Approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide Therapeutics\u2014A New Class of Cholesterol-Lowering Drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_79","unstructured":"(2021, October 01). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu."},{"key":"ref_80","first-page":"8129513","article-title":"Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9\u2014A Narrative Review","volume":"2022","author":"Reiner","year":"2022","journal-title":"Cardiovasc. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14740338.2019.1620730","article-title":"Safety and tolerability of injectable lipid-lowering drugs: An update of clinical data","volume":"18","author":"Strilchuck","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): Results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of antisense oligonucleotide and siRNA-based therapeutics","volume":"22","author":"Chi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_84","first-page":"100127","article-title":"Efficacy and safety of inclisiran a newly approved FDA drug: A systematic review and pooled analysis of available clinical studies","volume":"13","author":"Cicero","year":"2022","journal-title":"Am. Heart J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug Antibodies in Patients Treated with Alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies","volume":"95","author":"Wright","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mayocp.2019.11.010","article-title":"Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran","volume":"95","author":"Zijlstra","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"10742484221100107","DOI":"10.1177\/10742484221100107","article-title":"A Comprehensive Review of PCSK9 Inhibitors","volume":"27","author":"Coppinger","year":"2022","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Hermel, M., Lieberman, M., Slipczuk, L., Rana, J.S., and Virani, S.S. (2023). Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia-The Future Is Here. Pharmaceutics., 15.","DOI":"10.3390\/pharmaceutics15020459"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jacc.2021.01.008","article-title":"Inclisiran: A Game Changer in a Changing Game","volume":"77","author":"Vijay","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ihj.2015.05.020","article-title":"LDL Cholesterol, Statins And PCSK 9 Inhibitors","volume":"67","author":"Gupta","year":"2015","journal-title":"Indian Heart J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11883-022-01056-0","article-title":"Inclisiran: How Widely and When Should We Use It?","volume":"24","author":"Pirillo","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Koenig, W., Conde, L.G., Landmesser, U., Leiter, L.A., Ray, K.K., Schwartz, G.G., and Raal, F.J. (2022). Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther., Available online: https:\/\/linkspringer.53yu.com\/article\/10.1007\/s10557-022-07413-0.","DOI":"10.1007\/s10557-022-07413-0"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Clinical Research Epidemiology and prevention Inclisiran and cardiovascular events: A patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_96","unstructured":"(2023, January 15). U.S. National Library of Medicine, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03851705."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/eurjpc\/zwab224","article-title":"Major adverse cardiovascular events in homozygous familial hypercholesterolaemia: A systematic review and meta-analysis","volume":"29","author":"Kramer","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tcm.2020.03.004","article-title":"Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels","volume":"31","author":"Bianconi","year":"2020","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_99","first-page":"76","article-title":"Current Therapy for Homozygous Familial Hypercholesterolaemia","volume":"6","author":"Aldono","year":"2021","journal-title":"EMJ."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: Current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"37","DOI":"10.12997\/jla.2023.12.1.37","article-title":"New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)","volume":"12","author":"Kim","year":"2023","journal-title":"J. Lipid Atheroscler."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","article-title":"Existing and emerging strategies to lower Lipoprotein(a)","volume":"349","author":"Schwartz","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Walker, H.E., Rizzo, M., Fras, Z., Jug, B., Banach, M., and Penson, P.E. (2021). CRISPR Gene Editing in Lipid Disorders and Athero-sclerosis: Mechanisms and Opportunities. Metabolites, 9.","DOI":"10.3390\/metabo11120857"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"20150496","DOI":"10.1098\/rstb.2015.0496","article-title":"CRISPR-Cas: Biology, mechanisms and relevance","volume":"371","author":"Hille","year":"2016","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11886-017-0830-5","article-title":"Genome Editing for the Study of Cardiovascular Diseases","volume":"19","author":"Chadwick","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrcardio.2016.139","article-title":"Genome editing in cardiovascular diseases","volume":"14","author":"Strong","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo\u2014Brief Report","volume":"36","author":"Wang","year":"2016","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s11886-022-01782-6","article-title":"PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection","volume":"24","author":"Arnold","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.atherosclerosis.2019.06.019","article-title":"Safety, Tolerability and Ldl-C Reduction with a Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study","volume":"287","author":"Stein","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"eabe9117","DOI":"10.1126\/scitranslmed.abe9117","article-title":"An oral antisense oligonucleotide for PCSK9 inhibition","volume":"13","author":"Gennemark","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_113","unstructured":"ClinicalTrials.gov NCT05261126 (2022, June 17). A Study of the Efficacy and Safety of MK-0616 (Oral PCSK9 Inhibitor) in Adults with Hyper-cholesterolemia (MK-0616-008), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05261126."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Liu, C., Chen, J., Chen, H., Zhang, T., He, D., Luo, Q., Chi, J., Hong, Z., Liao, Y., and Zhang, S. (2022). PCSK9 Inhibition: From Current Advances to Evolving Future. Cells, 11.","DOI":"10.3390\/cells11192972"},{"key":"ref_115","first-page":"e573","article-title":"The clinical safety, pharmacokinetics, and LDL-cholesterol lowering efficacy of MK-0616, an oral PCSK9 inhibitor","volume":"144","author":"Johns","year":"2021","journal-title":"Circulation"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1093\/eurheartj\/ehab299","article-title":"PCSK9 vaccine: So near, yet so far!","volume":"42","author":"Sahebkar","year":"2021","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6858\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:11:22Z","timestamp":1760123482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":116,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24076858"],"URL":"https:\/\/doi.org\/10.3390\/ijms24076858","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}